Emmanuel Papadakis analyst DEUTSCHE BANK

Currently, out of the existing stock ratings of Emmanuel Papadakis - 3 which are a Sell (9.68%), 6 which are a Hold (19.35%), 22 which are a Buy (70.97%)

Emmanuel Papadakis

Work Performance Price Targets & Ratings Chart

Analyst Emmanuel Papadakis works at DEUTSCHE BANK and is covering the Healthcare sector with 169 price targets and ratings displayed on 14 stocks. Previously, Emmanuel Papadakis worked at BARCLAYS.

Emmanuel Papadakis's average stock forecast success ratio is 48.2% with an average time for price targets to be met of 47.91 days.

Most recent stock forecast was given on MRNA, Moderna at 03-Aug-2023.

Wall Street Analyst Emmanuel Papadakis

Analyst best performing recommendations are on ALVO.
The best stock recommendation documented was for MRNA (MODERNA) at 3/7/2022. The price target of $155 was fulfilled within 9 days with a profit of $28.54 (22.57%) receiving and performance score of 25.08.

Average potential price target upside

AZN AstraZeneca PLC GLPG Galapagos NV GRFS GSK GlaxoSmithKline plc MRNA Moderna NVO NVS Novartis AG SNY ARGX argenx SE GMAB Genmab A/S MOR ALVO LBTSF RHHBY

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

Buy

120.34

2 months 7 days ago

0/2 (0%)

$56.72 (106.69%)

Hold

2 months 9 days ago

0/2 (0%)

$56.95 (106.34%)

Buy

158.61

2 months 16 days ago

0/3 (0%)

$77.98 (168.75%)

Buy

80

$12.04 (17.72%)

85

3 months 26 days ago

1/3 (33.33%)

$9.27 (13.19%)

232

Buy

6 months 6 days ago

0/3 (0%)

$83.57 (142.93%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Emmanuel Papadakis is most bullish on?

Potential upside of $21.47 has been obtained for MRNA (MODERNA)

Which stock is Emmanuel Papadakis is most reserved on?

Potential downside of -$0 has been obtained for AZN (ASTRAZENECA PLC)

What Year was the first public recommendation made by Emmanuel Papadakis?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart